Scarica l'app Stockscreener
1.11
0.91%
0.01
Dopo l'orario di chiusura:
1.12
0.01
+0.90%
In 8 Bio Inc Borsa (INAB) Ultime notizie
symbol__ Stock Quote Price and Forecast - CNN
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
BRVE SEC FilingsBraveheart Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - TradingView
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss - Stock Titan
Large equity grants for TELA Bio, Inc. (TELA) CEO Heather Getz - Stock Titan
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
Heather Getz named CEO of TELA Bio as Antony Koblish exits - TradingView
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Q32 Bio Inc. (QTTB) investors disclose 5.49% stake in Schedule 13G/A - Stock Titan
Tevogen Inc. (NASDAQ: TVGN) changes name from Tevogen Bio Holdings - Stock Titan
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Tevogen Bio Holdings Inc. Becomes Tevogen Inc. - GlobeNewswire
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oak Hill Bio, Research Alliance III (RACC) plan SPAC merger - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
D. E. Shaw group reports 7.1% stake in Gossamer Bio (GOSS) - Stock Titan
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Kala Bio, Inc. Files Form 8-K with SEC Detailing Nasdaq Listing and Corporate Information - Minichart
Nuvation Bio sets Aug. 6 webcast on cancer treatment updates - Stock Titan
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
Entera Bio (NASDAQ: ENTX) expands share authorization and equity plan pool - Stock Titan
Bio-Path Holdings (BPTH) plans AML trial restart and crypto treasury - Stock Titan
63,969 shares bought by Tang Capital in Boundless Bio, Inc. (BOLD) - Stock Titan
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Gossamer Bio (NASDAQ: GOSS) wins approval to boost authorized shares to 4.0B - Stock Titan
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Q32 Bio (QTTB) shows Phase 2a alopecia areata responses with bempikibart - Stock Titan
[8-K] Q32 Bio Inc. Reports Material Event - Stock Titan
Experimental alopecia areata drug sees 40% of patients hit key hair regrowth mark - Stock Titan
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
Q32 Bio posts positive 36-week SIGNAL-AA Part B topline results; plans registrational program in H1 2027 - TradingView
Gossamer Bio (GOSS) Proxy filing Summary - Quartr
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 - TradingView
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma - GlobeNewswire Inc.
Kevin Tang’s Tang Capital buys $141,864 in Boundless Bio (BOLD) By Investing.com - Investing.com India
Form 4 Boundless Bio Inc For: 8 July By Investing.com - Investing.com Canada
Ten percent owner of Boundless Bio (NASDAQ: BOLD) adds shares - Stock Titan
Form 4 Palisade Bio Inc For: 8 July By Investing.com - Investing.com Nigeria
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):